It is well known that a majority of patients with non-valvular atrial fibrillation
(NVAF) treated with vitamin K antagonists (VKA) do not benefit from bridging anticoagulation
for ambulatory procedures [
1
,
2
,
- Doherty J.U.
- Gluckman T.J.
- Hucker W.J.
- et al.
2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation
in patients with nonvalvular atrial fibrillation: A report of the American college
of cardiology clinical expert consensus document task force.
J Am Coll Cardiol. 2017; 69: 871-898
3
]. Conversely, there is little evidence around overlapping low-molecular weight heparin
(LMWH) with VKA when starting anticoagulation, despite it being common practice. The
present study aimed to describe the frequency of use of an overlapping strategy and
determine the incidence of bleeding and thrombotic events based on whether this strategy
or VKA were used.- Vivas D.
- Roldán I.
- Ferrandis R.
- et al.
Perioperative and periprocedural management of antithrombotic therapy: Consensus document
of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC,
SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU.
Rev Esp Cardiol. 2018; 71: 553-564
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Perioperative bridging anticoagulation in patients with atrial fibrillation.N Engl J Med. 2015; 373: 823-833
- 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: A report of the American college of cardiology clinical expert consensus document task force.J Am Coll Cardiol. 2017; 69: 871-898
- Perioperative and periprocedural management of antithrombotic therapy: Consensus document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU.Rev Esp Cardiol. 2018; 71: 553-564
- Subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.J Thromb Haemost. 2005; 3: 692-694
- Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.J Thromb Haemost. 2012; 10: 692-694
- Short-term risk of bleeding during heparin bridging at initiation of vitamin k antagonist therapy in more than 90 000 patients with nonvalvular atrial fibrillation managed in outpatient care.J Am Heart Assoc. 2016; 5e004065
- Bridging anticoagulation.J Am Coll Cardiol. 2015; 66: 1392-1403
- Current trends in anticoagulation bridging for patients with chronic atrial fibrillation on warfarin undergoing endoscopy.Am J Cardiol. 2018; 121: 1548-1551
- Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: Findings from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF).Circulation. 2015; 131: 488-494
Article info
Publication history
Published online: September 28, 2018
Accepted:
September 25,
2018
Received:
September 21,
2018
Identification
Copyright
© 2018 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
